Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
May 14, 2024 06:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an...
Codexis Reports First Quarter 2024 Financial Results
May 02, 2024 16:05 ET
|
Codexis, Inc.
Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer ...
Codexis to Report First Quarter 2024 Financial Results on May 2
April 18, 2024 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first...
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
April 11, 2024 07:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., April 11, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Carole Cobb, MBA, to the Company’s...
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
February 28, 2024 16:05 ET
|
Codexis, Inc.
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected...
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
February 26, 2024 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an...
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
February 26, 2024 08:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health...
Codexis Announces Appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to Strategic Advisory Board
February 20, 2024 08:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD,...
Codexis to Report Fourth Quarter and Fiscal Year 2023 Financial Results on February 28
February 14, 2024 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth...
Codexis Secures $40 Million in Strategic Financing Deal with Innovatus Capital Partners to Further Strengthen Cash Position Ahead of Key Milestones
February 13, 2024 16:05 ET
|
Codexis, Inc.
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and...